The estimated Net Worth of Albert D. Dyrness is at least $23.6 Тысяча dollars as of 30 May 2023. Albert Dyrness owns over 23,255 units of Sonnet BioTherapeutics Inc stock worth over $23,613 and over the last 8 years Albert sold SONN stock worth over $0.
Albert has made over 2 trades of the Sonnet BioTherapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Albert bought 23,255 units of SONN stock worth $10,930 on 30 May 2023.
The largest trade Albert's ever made was buying 23,255 units of Sonnet BioTherapeutics Inc stock on 30 May 2023 worth over $10,930. On average, Albert trades about 3,208 units every 135 days since 2016. As of 30 May 2023 Albert still owns at least 28,962 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Albert Dyrness stock trades at the bottom of the page.
Albert's mailing address filed with the SEC is 100 OVERLOOK CENTER, SUITE 102, , PRINCETON,, NJ, 08540.
Over the last 7 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith и Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: